¶ Cannabis Law in Australia
🚨 Danger
Disclaimer: This page is provided for educational purposes only and does not constitute legal advice. Cannabis laws change frequently. Always verify current law in your jurisdiction and consult qualified legal counsel before taking action. CannaGrow accepts no liability for actions taken based on this content.
Australia legalized medical cannabis in 2016 through the Narcotic Drugs Amendment Act, establishing a federal framework for patient access through the Therapeutic Goods Administration (TGA). Patients access medical cannabis primarily through two pathways: the Special Access Scheme (SAS), which requires individual approval for each prescription, and the Authorised Prescrier pathway, which allows approved doctors to prescribe to multiple patients without individual TGA applications.
Despite the medical program, recreational cannabis remains illegal under federal law. This creates a notable contradiction in the Australian Capital Territory (ACT), which voted in 2019 to legalize personal possession and cultivation of small amounts of cannabis (effective 2020). The ACT law conflicts with federal prohibition, creating a legal gray area in which the territory's legalization is legally valid under territory law but potentially overridden by federal law. The federal government has not actively enforced federal prohibition against ACT-compliant behavior, but the conflict remains unresolved.
Australia's medical cannabis program has been widely criticized as slow, expensive, and limited. Most medical cannabis products are imported, as domestic production has been slow to develop. Patients face significant barriers including high costs, limited product availability, and bureaucratic hurdles. Many patients continue to rely on the illicit market despite the existence of a legal medical pathway. At the same time, some Australian states maintain some of the world's strictest cannabis penalties for recreational possession and supply, creating a country where the legal landscape varies enormously from state to state and territory to territory.
¶ Related Pages
| Page | Description |
|---|---|
| Law Policy | Global overview of cannabis law and policy |
| United Kingdom | Cannabis law in the United Kingdom — strict medical access |
| Israel | Cannabis law in Israel — world-leading research |
| Colombia | Cannabis law in Colombia — export-oriented medical framework |
| War On Drugs | The War on Drugs and its global impact |
| Modern Legalization | The modern legalization movement |
| Law Policy | Legal rights and harm reduction |
| Glossary | Cannabis terminology and definitions |
¶ Current Legal Status
| Parameter | Detail |
|---|---|
| Recreational legality (federal) | Illegal. Cannabis is a controlled substance under federal law. |
| Medical legality (federal) | Legal since 2016 (Narcotic Drugs Amendment Act). Access through TGA-regulated pathways. |
| Legal framework (federal) | Narcotic Drugs Act 1967 (as amended 2016); Therapeutic Goods Act 1989; Special Access Scheme (SAS); Authorised Prescrier scheme; state and territory legislation |
| ACT personal possession | Legalized under territory law (effective 2020): possession of up to 50 grams, cultivation of up to 2 plants per person (max 4 per household). Conflicts with federal law. |
| Medical access pathways | Special Access Scheme (SAS-B) — individual TGA approval for each prescription; Authorised Prescrier — approved doctors can prescribe without individual applications; Unapproved Cannabis Products pathway |
| Domestic production | Licensed domestic cultivation and manufacturing is permitted under federal license. Production has grown but remains limited. |
| CBD products | Low-dose CBD (up to 150mg/day) was rescheduled to pharmacist-only (Schedule 3) in 2021, but no products have been approved for Schedule 3 sale. CBD products require prescription (Schedule 4). |
| Penalties (recreational, varies by state) | Varies enormously by state and territory. Some states impose imprisonment for possession; others have diversion programs. |
| Key date | February 2016 — Narcotic Drugs Amendment Act passed, legalizing medical cannabis production and access. January 2020 — ACT personal possession law took effect. |
¶ Historical Background
¶ Pre-2016 Prohibition
Before 2016, cannabis was fully prohibited under Australian federal law:
- The Narcotic Drugs Act 1967 prohibited cannabis production and possession
- Medical cannabis was not available through any legal pathway
- Patients who needed cannabis faced criminal prosecution
- Several high-profile cases drew public attention to the need for medical access
¶ Medical Cannabis Legalization (2016)
The Narcotic Drugs Amendment Act 2016 was the pivotal reform:
- Passed with bipartisan support in the federal Parliament
- Amended the Narcotic Drugs Act 1967 to permit licensed cultivation, production, and manufacture of cannabis for medical and scientific purposes
- Established a licensing system administered by the Office of Drug Control (ODC)
- The TGA regulates patient access through existing medical product frameworks (SAS and Authorised Prescrier)
The reform was driven by:
- Advocacy from patients and families (particularly parents of children with severe epilepsy)
- Growing international evidence for cannabis's therapeutic applications
- Shifting public opinion (polling showed strong majority support for medical cannabis)
- Political recognition that the prohibitionist status quo was unsustainable
¶ ACT Legalization (2019-2020)
In a bold move, the Australian Capital Territory (ACT) Legislative Assembly passed legislation in 2019 to legalize personal possession and cultivation of small amounts of cannabis:
| ACT Provision | Detail |
|---|---|
| Personal possession | Up to 50 grams per person |
| Home cultivation | Up to 2 plants per person, maximum 4 plants per household |
| Public consumption | Prohibited |
| Effective date | January 31, 2020 |
The ACT law creates a direct conflict with federal law:
- Under the Australian constitutional framework, federal law prevails over territory law in the event of a conflict
- The federal government has the power to override the ACT law but has not done so
- Federal police (AFP) have stated they will not prioritize enforcement against ACT-compliant behavior
- The conflict remains legally unresolved
¶ State-by-State Variation
Australia's federalist structure means that criminal penalties for recreational cannabis vary by state and territory:
| Jurisdiction | Recreational Status | Notes |
|---|---|---|
| ACT | Personal possession and cultivation legalized (territory law) | Conflicts with federal law |
| South Australia | Civil penalty scheme (de facto decriminalization since 1987) | Minor possession results in fine, not criminal charge |
| Northern Territory | Civil penalty scheme | Similar to SA |
| Other states | Criminal penalties | Varying severity — some impose imprisonment for possession |
¶ Key Legislation
| Law/Policy | Year | Effect |
|---|---|---|
| Narcotic Drugs Act 1967 | 1967 | Original federal drug prohibition framework |
| Narcotic Drugs Amendment Act | 2016 | Legalized medical cannabis production and access at federal level; established ODC licensing |
| Therapeutic Goods Act 1989 | 1989 (applies to cannabis access) | Governs TGA regulation of therapeutic products, including medical cannabis |
| Special Access Scheme (SAS) regulations | Various | Framework for individual patient access to unapproved medicines, including cannabis |
| Authorised Prescrier scheme regulations | Various | Framework allowing approved doctors to prescribe unapproved medicines without individual applications |
| ACT Drugs of Dependence Amendment Act | 2019 | Legalized personal possession (50g) and cultivation (2 plants/person, max 4/household) in the ACT |
| State-level drug laws | Various | Each state and territory has its own criminal penalties for recreational cannabis |
¶ How the System Works
¶ Medical Cannabis Access Pathways
Patients access medical cannabis through several pathways:
| Pathway | Description | Process |
|---|---|---|
| Special Access Scheme (SAS-B) | Most common pathway. Doctor applies to TGA for approval to prescribe cannabis to a specific patient. | Doctor identifies patient need, submits SAS-B application to TGA, TGA approves (usually within days to weeks), doctor prescribes, patient obtains product from pharmacy. |
| Authorised Prescrier (AP) | Doctor obtains AP status from TGA, allowing them to prescribe cannabis to multiple patients without individual applications. | Doctor applies for AP status (one-time process), TGA approves, doctor can then prescribe to eligible patients without further TGA applications. |
| Clinical trials | Limited access through approved research studies. | Patient enrolls in clinical trial; cannabis is provided as part of study protocol. |
¶ Product Availability
Medical cannabis products available in Australia include:
| Product Type | Availability |
|---|---|
| Dried flower | Available, but limited. Most products are imported. |
| Oils and extracts | Available. Commonly prescribed. |
| Capsules | Limited availability. |
| Topicals | Limited availability. |
Most products are imported from licensed producers in other countries (including Canada and Israel). Domestic production has grown but remains a minority of supply.
¶ Cost and Insurance
Medical cannabis in Australia is not subsidized by the Pharmaceutical Benefits Scheme (PBS) for most products:
- Patients pay out-of-pocket costs, which can be significant
- Average monthly costs range from AUD 100 to AUD 500+ depending on product and dose
- Some private health insurers provide partial coverage
- The lack of PBS subsidy is a major barrier to access
¶ Domestic Production
Australia has established a licensed domestic production industry:
- The Office of Drug Control (ODC) licenses cultivators, producers, and manufacturers
- Licensed facilities must meet strict security and quality standards
- Domestic production has grown but remains limited relative to demand
- Australia's climate is well-suited to cannabis cultivation
- Export of Australian-produced cannabis is permitted under international treaty framework
¶ Social Justice and Equity
¶ Indigenous Australians
Indigenous Australians have a traditional history of cannabis use that predates European colonization:
- Cannabis was introduced to Australia by European colonizers, but Indigenous peoples in some regions adopted its use
- Indigenous communities have not benefited proportionally from the medical cannabis program
- Access barriers (cost, geographic distance from healthcare providers, cultural barriers) disproportionately affect Indigenous patients
- Some Indigenous communities have advocated for culturally appropriate medical cannabis access
¶ Access Inequality
The Australian medical cannabis program has significant equity issues:
| Issue | Description |
|---|---|
| Cost | Out-of-pocket costs are prohibitive for many patients, particularly those on low incomes. |
| Geographic access | Patients in rural and remote areas face significant barriers to accessing prescribing doctors and pharmacies. |
| Doctor knowledge | Many doctors lack training or confidence in prescribing cannabis, limiting patient access. |
| PBS exclusion | The lack of Pharmaceutical Benefits Scheme subsidy means medical cannabis is not accessible through the subsidized medication system that Australians rely on for other prescription drugs. |
¶ Strict State Penalties
Some Australian states maintain harsh criminal penalties for recreational cannabis:
- Penalties vary enormously between states
- Some states impose imprisonment for possession
- Diversion programs (redirecting offenders to education or treatment rather than prosecution) exist in some states but not others
- Enforcement disparities affect marginalized communities disproportionately
¶ ACT's Reform and Its Limits
The ACT's legalization of personal possession and cultivation:
- Does not address social equity or expungement
- Does not create a legal commercial supply chain (possession and cultivation are legal, but sale is not)
- Consumers must still source cannabis from the illicit market or grow their own
- The federal-state conflict creates ongoing legal uncertainty
¶ Public Opinion and Politics
¶ Overwhelming Support for Medical Cannabis
Australian public opinion on medical cannabis is consistently and strongly supportive:
| Metric | Estimate |
|---|---|
| Support for medical cannabis | 85-90%+ in polls |
| Support for recreational legalization | Approximately 60-70% (growing) |
| Support for decriminalization | Strong majority |
Medical cannabis is one of the most broadly supported policy reforms in modern Australian politics, with support across the political spectrum.
¶ Political Landscape
| Party/Group | Position |
|---|---|
| Australian Labor Party | Supports medical cannabis; some members support broader reform |
| Liberal Party of Australia | Supports medical cannabis; generally cautious on recreational reform |
| The Greens | Supports full legalization and decriminalization; most pro-reform party |
| National Party | Generally more conservative; cautious on reform |
¶ Federal Government Position
The federal government has:
- Supported medical cannabis access while maintaining recreational prohibition
- Not acted to override the ACT's legalization law
- Not advanced recreational legalization at the federal level
- Focused medical cannabis policy on expanding access and reducing costs
¶ Challenges and Criticisms
¶ Slow and Bureaucratic Access
The most significant criticism of Australia's medical cannabis program is that access is slow and bureaucratic:
- SAS-B applications require doctor time and TGA processing
- While TGA approval rates are high (most applications are approved), the process creates delays
- Many doctors are unfamiliar with the application process and reluctant to engage
- Patients report waiting weeks or months for access
¶ High Costs
Medical cannabis in Australia is expensive:
- Products are not PBS-subsidized for most patients
- Monthly costs of AUD 100-500+ are beyond the reach of many patients
- Some patients continue to use the illicit market because legal products are unaffordable
- Advocates have called for PBS listing to reduce costs
¶ Limited Product Range
The Australian medical cannabis market has a limited product range:
- Most products are imported
- Domestic production is growing but limited
- Product variety is narrower than in more mature markets (Canada, US legal states)
- Patients may not find products that match their specific therapeutic needs
¶ Illicit Market Persistence
The illicit market for cannabis remains significant in Australia:
- Medical access barriers (cost, bureaucracy) drive some consumers to the illicit market
- Recreational demand is entirely served by the illicit market
- Australia's geographic isolation has historically kept cannabis prices high
- The black market competes with the legal medical market on price and accessibility
¶ Federal-State Conflict
The ACT's legalization creates an unresolved constitutional tension:
- Federal law prohibits cannabis possession and cultivation
- ACT law permits it (within limits)
- The federal government has not enforced federal law against ACT-compliant behavior
- But the legal conflict could be tested in court at any time
- This uncertainty affects patients, cultivators, and policymakers
¶ International Context
¶ Australia's Position in Global Reform
Australia's medical cannabis program places it in the middle tier of global cannabis reform:
| Country | Comparison |
|---|---|
| Canada | Full legalization; Australia has medical-only. |
| Germany | Full legalization (2024); Australia has medical-only. |
| United Kingdom | Medical-only (since 2018); similar to Australia but with even more limited access. |
| Israel | Medical with relatively accessible program and world-leading research; Australia's program is more bureaucratic. |
| New Zealand | Medical program; 2020 legalization referendum narrowly failed. |
¶ International Medical Cannabis Standards
Australia has contributed to international medical cannabis standards:
- Australian regulatory frameworks (TGA, ODC) are studied by other nations designing medical cannabis programs
- Australian clinical research on cannabis is respected internationally
- Australia's licensing and quality control standards are among the strictest globally
¶ Export Potential
Australia has the potential to become a significant cannabis exporter:
- Favorable climate for cultivation
- Strong regulatory framework
- Existing agricultural export infrastructure
- Licensed exporters have begun shipping medical cannabis to other nations
- International trade is constrained by treaty obligations and importing nations' regulations
¶ Key Takeaways
| Point | Summary |
|---|---|
| Australia legalized medical cannabis in 2016. | Access is through the SAS and Authorised Prescrier pathways regulated by the TGA. |
| Recreational cannabis remains illegal federally. | The ACT legalized personal possession and cultivation in 2020, creating a federal-territory conflict. |
| Access has been criticized as slow and expensive. | Products are not PBS-subsidized; costs are high; bureaucratic barriers exist. |
| Domestic production is growing but limited. | Most products are imported. Australia has export potential. |
| Indigenous Australians have traditional cannabis use history. | They have not proportionally benefited from the medical program. |
| Some states maintain harsh recreational penalties. | Australia has some of the world's strictest cannabis penalties at the state level. |
Last reviewed: April 2026. Verify current law independently before making decisions based on this content.